Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company specializing in novel serotonergic agonists (NSAs), announced that CEO Michael Halstead will participate in a fireside chat at the Cantor Global Healthcare Conference, scheduled for September 9-11, 2026, in New York City. The session is set to be webcast live on September 11 at 8 a.m. EDT, with a replay available on the company's investor relations website.
This appearance comes at a pivotal time for Helus Pharma, which is advancing its pipeline of proprietary NSAs designed to target serotonin pathways believed to promote neuroplasticity—the brain's ability to reorganize itself. The company's lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder (MDD) and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA). This designation is granted to therapies that may offer substantial improvement over existing treatments for serious or life-threatening conditions, potentially expediting their development and review.
In addition, Helus Pharma is evaluating HLP004, another proprietary NSA, in Phase 2 trials for generalized anxiety disorder (GAD). The company also maintains an extensive research portfolio of investigational NSAs, reflecting its commitment to addressing the large unmet need for individuals suffering from depression, anxiety, and other mental health conditions.
The company's focus on NSAs represents a significant shift from traditional psychedelic-assisted therapy, as these synthetic molecules are designed to deliver the therapeutic benefits of psychedelics without the hallucinogenic effects. This approach could make treatments more accessible and acceptable to a broader patient population and healthcare providers, potentially transforming the mental health treatment landscape.
Industry analysts suggest that Helus Pharma's progress is indicative of a broader trend in the psychedelics sector, where companies are moving beyond research into late-stage clinical trials and toward potential commercialization. The participation of its CEO at a major healthcare conference highlights the growing interest from institutional investors and the pharmaceutical industry in these novel treatments.
Helus Pharma, the commercial operating name of Cybin Inc., founded in 2019, operates in Canada, the United States, the United Kingdom, and Ireland. The company aims to improve mental health outcomes through the introduction of NSAs that provide durable improvements, potentially offering new hope for patients who have not responded to conventional therapies.
The fireside chat at the Cantor Global Healthcare Conference will provide an opportunity for investors and industry stakeholders to gain insights into Helus Pharma's strategic direction, clinical milestones, and future plans. For those unable to attend the live session, the webcast replay will be accessible via the Events & Presentations page of the company's investor relations website.
For more information about Helus Pharma and its pipeline, visit www.helus.com.
This announcement was disseminated by PsychedelicNewsWire, a communications platform focusing on the psychedelics sector. For the full press release, see https://ibn.fm/cNoh4.
